Literature DB >> 30032996

Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions.

Médéa Locquet1, Charlotte Beaudart2, Manon Hajaoui2, Jean Petermans3, Jean-Yves Reginster3, Olivier Bruyère2.   

Abstract

OBJECTIVES: To assess the occurrence of 3 major adverse outcomes of sarcopenia (ie, physical disabilities, institutionalizations and deaths) observed over a 3-year follow-up in older adults and compare the risk of these outcomes using 5 definitions of sarcopenia.
DESIGN: The study is a part of the ongoing SarcoPhAge (for Sarcopenia and Physical Impairment with advancing Age) longitudinal project. SETTING AND PARTICIPANTS: The SarcoPhAge study follows 534 community-dwelling older adults. MEASURES: Sarcopenia was defined as low muscle mass plus a decreased muscle function. Data on adverse outcomes were collected yearly during the annual follow-up or with a phone call. The association between baseline sarcopenia and the occurrence of undesirable outcomes was tested using the Cox proportional hazards model or a logistic regression model.
RESULTS: A total of 534 subjects were recruited into this prospective cohort (73.5 ± 6.2 years, 60.5% female). After 3 years, 33 participants were lost to follow-up. If no association between baseline sarcopenia and physical disabilities or institutionalizations was highlighted, a higher number of deaths occurred in individuals diagnosed with sarcopenia than in those who were not diagnosed (16.2% vs 4.6%, P value <.001). The probability of death within 3 years when presenting with sarcopenia showed an approximately 3-fold increase compared to subjects without sarcopenia.
CONCLUSION: Over a 3-year period, sarcopenia at baseline was associated with an increased risk of mortality. There were some variations in the ability of different definitions of sarcopenia to predict outcomes.
Copyright © 2018 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SarcoPhAge; Sarcopenia; consequences; mortality; prospective study

Mesh:

Year:  2018        PMID: 30032996     DOI: 10.1016/j.jamda.2018.06.004

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  9 in total

1.  Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People.

Authors:  Nathalia Perleberg Bachettini; Renata Moraes Bielemann; Thiago Gonzalez Barbosa-Silva; Ana Maria Baptista Menezes; Elaine Tomasi; Maria Cristina Gonzalez
Journal:  Eur J Clin Nutr       Date:  2019-10-04       Impact factor: 4.016

2.  Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL.

Authors:  A Geerinck; C Beaudart; J-Y Reginster; M Locquet; C Monseur; S Gillain; O Bruyère
Journal:  Qual Life Res       Date:  2021-03-30       Impact factor: 4.147

3.  Nutrition, Physical Exercise, and the Prevalence of Sarcopenia in Elderly Residents in Nursing Homes in China.

Authors:  Li-Jun Yang; Guan-Hui Wu; Yun-Long Yang; Yong-Hua Wu; Li Zhang; Min-Hong Wang; Li-Ya Mo; Gang Xue; Chuan-Zhi Wang; Xiao-Fen Weng
Journal:  Med Sci Monit       Date:  2019-06-13

4.  Automatic Classification of Sarcopenia Level in Older Adults: A Case Study at Tijuana General Hospital.

Authors:  Cristián Castillo-Olea; Begonya García-Zapirain Soto; Christian Carballo Lozano; Clemente Zuñiga
Journal:  Int J Environ Res Public Health       Date:  2019-09-06       Impact factor: 3.390

5.  European Working Group on Sarcopenia in Older People 2010 (EWGSOP1) and 2019 (EWGSOP2) criteria or slowness: which is the best predictor of mortality risk in older adults?

Authors:  Maria Claudia Bernardes Spexoto; Paula Camila Ramírez; Roberta de Oliveira Máximo; Andrew Steptoe; Cesar de Oliveira; Tiago da Silva Alexandre
Journal:  Age Ageing       Date:  2022-07-01       Impact factor: 12.782

6.  Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study.

Authors:  Dolores Sanchez-Rodriguez; Médéa Locquet; Jean-Yves Reginster; Etienne Cavalier; Olivier Bruyère; Charlotte Beaudart
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-07-13       Impact factor: 12.910

Review 7.  Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science.

Authors:  Alessia Lena; Markus S Anker; Jochen Springer
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

8.  Signatures and Clinical Significance of Amino Acid Flux in Sarcopenia: A Systematic Review and Meta-Analysis.

Authors:  Miao Dai; Taiping Lin; Jirong Yue; Lunzhi Dai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-13       Impact factor: 5.555

9.  The Combined Usage of the Global Leadership Initiative on Malnutrition Criteria and Controlling Nutrition Status Score in Acute Care Hospitals.

Authors:  Asako Mitani; Takahito Iwai; Toshiaki Shichinohe; Hiroshi Takeda; Satomi Kumagai; Mutsumi Nishida; Junichi Sugita; Takanori Teshima
Journal:  Ann Nutr Metab       Date:  2021-07-16       Impact factor: 3.374

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.